ProQR Therapeutics N.V. buy Chardan Capital
Start price
10.05.24
/
50%
€1.86
Target price
10.05.25
€2.32
Performance (%)
-13.44%
Price
15.07.24
€1.61
Summary
This prediction is currently active. The prediction for ProQR Therapeutics N.V. disappoints with a performance of -13.44%. This prediction currently runs until 10.05.25. The prediction end date can be changed by Chardan_Capital at any time. Chardan_Capital has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
ProQR Therapeutics N.V. | 1.641% | 1.641% |
iShares Core DAX® | -3.033% | -0.013% |
iShares Nasdaq 100 | -3.554% | -2.546% |
iShares Nikkei 225® | -3.938% | 2.183% |
iShares S&P 500 | -1.517% | -0.882% |
Comments by Chardan_Capital for this prediction
In the thread ProQR Therapeutics N.V. diskutieren
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.
Ratings data for PRQR provided by MarketBeat
Stopped prediction by Chardan_Capital for ProQR Therapeutics N.V.
ProQR Therapeutics N.V.
Start price
Target price
Perf. (%)
€1.27
08.11.23
08.11.23
€1.87
08.11.24
08.11.24
27.17%
15.07.24
15.07.24